EU fines six for pay-for-delay

Share this article:

The European Union is fining drugmakers over efforts to keep generics of the blood-pressure drug perindopril off the market.

Bloomberg reports that the EU has fined six drugmakers, including brand owner Les Laboratories Servier ($451 million) and generic maker Teva ($21 million), over the pay-for-delay strategy which extended the brand's hold on the marketplace.

Bloomberg says the EU's accusations against Servier included making agreements with generics makers to keep generics out of pharmacies and acquiring competing technologies.

Krka Group, Mylan Laboratories, Unichem Laboratories and Lupin Ltd., were also fined.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters